Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > Reverse split is a necessity

<< Previous

Bullboard Posts

Next >>

Comment by zardoz00on Apr 28, 2021 9:32am

153 Views

Post# 33081414

RE:Reverse split is a necessity

It might be but in 90% of the cases independently of the value of the company, after a reverse split the shares go down as the predative shorters go into action. So, I will sell before the RS, wait for the price to drop and buy back at a better price. If I’m wrong then so be it.

<< Previous

Bullboard Posts

Next >>

Investors eye Australian gold mining projects amid promising developments